We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current CNSL market cap is 9.51M. The company's latest EPS is GBP -0.0162 and P/E is -2.47.
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 9.76M | 9.82M | 8.74M | 12.33M | 8.19M |
| Operating Income | 1.33M | -9.1M | -3.46M | -8.61M | -4.09M |
| Net Income | 974k | -6.83M | -2.1M | -11.33M | -3.86M |
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 23.48M | 18.84M | 29.55M | 17.84M | 14.41M |
| Total Liabilities | 5.29M | 5.23M | 6.16M | 6.02M | 4.45M |
| Total Equity | 18.19M | 13.61M | 23.38M | 11.82M | 9.95M |
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | 368k | 548k | -2.42M | -3.23M | -3.15M |
| Investing | -894k | -2.15M | -2.83M | -493k | 5.18M |
| Financing | 535k | 1.64M | 11.07M | -502k | 1.49M |
| Market Cap | 9.51M |
| Price to Earnings Ratio | -2.47 |
| Price to Sales Ratio | 1.16 |
| Price to Cash Ratio | 1.86 |
| Price to Book Ratio | 0.96 |
| Dividend Yield | - |
| Shares Outstanding | 237.69M |
| Average Volume (1 week) | 396.21k |
| Average Volume (1 Month) | 808.84k |
| 52 Week Change | 81.82% |
| 52 Week High | 4.10 |
| 52 Week Low | 1.725 |
| Spread (Intraday) | 0.2 (4.88%) |
| Company Name | Cambridge Nutritional Sciences Plc |
| Address |
omega house scotland FK12 5DQ |
| Website | https://www.omegadiagnostics.com |
| Industry | diversified industrial holding (D11) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
